BioCatalyst

IDYA — IDEAYA Biosciences, Inc. catalysts

2 verified catalyst event(s) for IDEAYA Biosciences, Inc. (ticker IDYA). Each is linked to its official source. Verified as of 2026-10-01.

Next verified catalyst

2027-01-15 — IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic U · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01-15
in 4mo
ESTIMATED
 READOUT
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Me
Phase 2/3 · Metastatic Uveal Melanoma
 IDYA IDEAYA Biosciences, Inc. IDE196, Crizotinib, Pembrolizumab, Ipili ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
2027-01-29
in 4mo
ESTIMATED
 READOUT
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRK
Phase 1/2 · Metastatic Uveal Melanoma, Cutaneous Melanoma
 IDYA IDEAYA Biosciences, Inc. IDE196, Binimetinib, Crizotinib ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.